RT Journal Article
T1 From Proof-of-Concept Material to PEGylated and Modularly Targeted Ultrasound-Responsive Mesoporous Silica Nanoparticles
A1 Paris, J. L.
A1 Villaverde Cantizano, Gonzalo
A1 Cabañas Criado, María Victoria
A1 Manzano García, Miguel
A1 Vallet Regí, María Dulce Nombre
AB In this work we present the synthesis, characterization and in vitro biological evaluation of PEGylated and actively-targeted ultrasound-responsive hybrid mesoporous silica nanoparticles. This work covers the development of the chemical strategies necessary to afford a modular nanocarrier starting from a proof-of-concept material presented in previous work. This functional ultrasound-responsive material can be adapted to different specific pathological conditions by carefully choosing the appropriate targeting moieties. The new ultrasound responsive material is able to target HeLa cells when conjugated with biotin or an RGD peptide. Ultrasound-responsive cytotoxicity towards cancer cells of doxorubicinloaded nanoparticles is demonstrated in an in vitro cytotoxicity assay.
PB Royal Society of Chemistry
SN 2050-750X
YR 2018
FD 2018-04-11
LK https://hdl.handle.net/20.500.14352/12028
UL https://hdl.handle.net/20.500.14352/12028
LA eng
NO Paris, J.  L., Villaverde Cantizano, G., Cabañas Criado, M. V. et al. «From Proof-of-Concept Material to PEGylated and Modularly Targeted Ultrasound-Responsive Mesoporous Silica Nanoparticles». Journal of Materials Chemistry B, vol. 6, n.o 18, 2018, pp. 2785-94. DOI.org (Crossref), https://doi.org/10.1039/C8TB00444G.
NO RESEARCHER ID D-9318-2017 (Juan Luis Paris de la Fuente)ORCID 0000-0001-8950-283X (Juan Luis Paris de la Fuente)RESEARCHER ID G-8740-2015 (María Victoria Cabañas Criado)ORCID 0000-0002-4753-5665 (María Victoria Cabañas Criado)RESEARCHER ID K-3719-2014 (Miguel Manzano García)ORCID 0000-0001-6238-6111 (Miguel Manzano García)RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)
NO Unión Europea
NO Ministerio de Economía, Comercio y Empresa (España)
DS Docta Complutense
RD 6 abr 2025